Junji Tsurutani

22PUBLICATIONS
97CO-AUTHORS
Disease surveillanceClinical midwiferyCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jan 31, 2026
Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan.

Junji Tsurutani, Kengo Noguchi, Ayumi Tanabe

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

Naoto T Ueno, Francesco Cottone, Kyle Dunton

|Jan 09, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita, Shigehira Saji, Toshimi Takano

|Nov 18, 2024
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Sayuka Nakayama, Ayuha Yoshizawa, Junji Tsurutani

Pageof 4

Frequent Collaborators

3 joint publications

William Jacot

3 joint publications

Erika P Hamilton

2 joint publications

Naoto T Ueno

2 joint publications

Toshimitsu Yamaoka